clinical trials

The ALS Association is partnering with MyTomorrows, a global health technology company, to make it easier for people with amyotrophic lateral sclerosis (ALS) to find and participate in clinical trials, and to know about “pre-approval treatment options,” the company said in a press release. The collaboration…

The technology company Unlearn has joined with QurAlis to use artificial intelligence (AI) to speed up clinincal trials for amyotrophic lateral sclerosis (ALS). The aim of the collaboration is to minimize variability and increase the statistical strength of QurAlis’ clinical trials that are evaluating their primary ALS…

Difficulties in measuring the progression of amyotrophic lateral sclerosis (ALS) among patients with advanced disease can cause complications in clinical trials, according to a new analysis that highlights how such problems may have affected the failed NurOwn study. The work was led by scientists at BrainStorm…

CuATSM, a potential amyotrophic lateral sclerosis (ALS) therapy that’s now in clinical trials, may work by altering how certain cells in the brain generate energy, a new study suggests. Researchers say these findings may help to identify patients most likely to respond to the experimental treatment. “Screening patient derived…

Brainstorm Cell Therapeutics is preparing to file an application with the U.S. Food and Drug Administration (FDA) requesting approval of its cell-based therapy NurOwn for amyotrophic lateral sclerosis (ALS). The decision to submit a biologics license application was based on “the totality of the evidence from NurOwn’s clinical…

The U.S. Food and Drug Administration (FDA) has published on its website a five-year action plan meant to help advance the development of — and access to — treatments that may make life better and longer for people with amyotrophic lateral sclerosis (ALS) or other rare neurodegenerative diseases. The…

NeuroSense Therapeutics’ combination therapy PrimeC led to a significant decline in certain biomarkers of amyotrophic lateral sclerosis (ALS) when used as an add-on to standard of care treatment, a study found. Standard treatment alone, meanwhile, appeared to have no impact on these disease-related biomarkers. The preliminary results come from…

The rarity of amyotrophic lateral sclerosis (ALS) in children makes it impossible to realistically conduct clinical trials of experimental medicines in this population, researchers across Europe argue in a paper. “Given the absence of consensus on pediatric ALS as a disease entity, the extremely low prevalence of ALS in…

The Canadian province of British Columbia is giving another CA$2 million (about $1.65 million) to help establish “Project Hope” — what organizers hope will be a world-class amyotrophic lateral sclerosis (ALS) center at the University of British Columbia (UBC). With the new funding, to the ALS Society…

In response to the National Institute of Neurological Disorders and Stroke‘s (NINDS) request for community input regarding what it should prioritize to accelerate amyotrophic lateral sclerosis (ALS) research, the ALS Association’s overarching message is this: move swiftly to help patients. NINDS, which is part of the National…